

Uceris® (budesonide) – First-time generic

- On April 28 2023, <u>Padagis launched</u> an <u>AB-rated</u> generic version of Bausch Health's <u>Uceris</u> (budesonide) rectal foam.
 - The FDA granted Padagis' generic Uceris 180-days of competitive generic therapy exclusivity.
- Uceris is approved for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.
- Uceris is also available generically as an oral <u>extended-release tablet</u> approved for the induction of remission in patients with active, mild to moderate ulcerative colitis.
- According to IQVIA, annual sales for Uceris were approximately \$13 million in the 12 months ended March 2023.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.